Thermo Fisher to Offer Senior Notes | GenomeWeb

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it intends to offer senior notes to cover the cost of its $925 million acquisition of One Lambda.

Thermo Fisher has not yet placed a value on the notes it intends to sell, but in a filing with the US Securities and Exchange Commission it said the notes would be due in 2018 and 2023. Joint book-running managers for the notes offering are Goldman Sachs, JP Morgan Securities, and RBS Securities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.